Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Thrombolysis with recombinant tissue plasminogen activator under dabigatran anticoagulation in experimental stroke.

Pfeilschifter W, Bohmann F, Baumgarten P, Mittelbronn M, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C.

Ann Neurol. 2012 May;71(5):624-33. doi: 10.1002/ana.23558. Epub 2012 Mar 23.

PMID:
22447744
2.

Anticoagulation with dabigatran does not increase secondary intracerebral haemorrhage after thrombolysis in experimental cerebral ischaemia.

Sun L, Zhou W, Ploen R, Zorn M, Veltkamp R.

Thromb Haemost. 2013 Jul;110(1):153-61. doi: 10.1160/TH12-12-0942. Epub 2013 Apr 25.

PMID:
23615682
3.

No influence of dabigatran anticoagulation on hemorrhagic transformation in an experimental model of ischemic stroke.

Bohmann F, Mirceska A, Pfeilschifter J, Lindhoff-Last E, Steinmetz H, Foerch C, Pfeilschifter W.

PLoS One. 2012;7(7):e40804. doi: 10.1371/journal.pone.0040804. Epub 2012 Jul 24.

4.

Warfarin anticoagulation exacerbates the risk of hemorrhagic transformation after rt-PA treatment in experimental stroke: therapeutic potential of PCC.

Pfeilschifter W, Spitzer D, Pfeilschifter J, Steinmetz H, Foerch C.

PLoS One. 2011;6(10):e26087. doi: 10.1371/journal.pone.0026087. Epub 2011 Oct 19.

5.

Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients.

Takeuchi S, Wada K, Nagatani K, Otani N, Osada H, Nawashiro H.

Acta Neurochir (Wien). 2012 Jan;154(1):87. doi: 10.1007/s00701-011-1196-x. Epub 2011 Oct 25. No abstract available.

PMID:
22037979
6.

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S.

Circulation. 2011 May 31;123(21):2363-72. doi: 10.1161/CIRCULATIONAHA.110.004747. Epub 2011 May 16.

7.

Reducing hemorrhagic complication by dabigatran via neurovascular protection after recanalization with tissue plasminogen activator in ischemic stroke of rat.

Kono S, Deguchi K, Omote Y, Yunoki T, Yamashita T, Kurata T, Ikeda Y, Abe K.

J Neurosci Res. 2014 Jan;92(1):46-53. doi: 10.1002/jnr.23302. Epub 2013 Nov 4.

8.

Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation--sub-analysis in Japanese population in RE-LY trial.

Hori M, Connolly SJ, Ezekowitz MD, Reilly PA, Yusuf S, Wallentin L; RE-LY Investigators.

Circ J. 2011;75(4):800-5. Epub 2011 Mar 19.

9.

Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.

Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M; RE-LY Investigators.

Circulation. 2012 Jul 17;126(3):343-8. doi: 10.1161/CIRCULATIONAHA.111.090464. Epub 2012 Jun 14. Erratum in: Circulation. 2012 Sep 4;126(10):e160. Heidbuchle, Hein [corrected to Heidbuchel, Hein].

10.

Increased risk of hemorrhagic transformation in ischemic stroke occurring during warfarin anticoagulation: an experimental study in mice.

Pfeilschifter W, Spitzer D, Czech-Zechmeister B, Steinmetz H, Foerch C.

Stroke. 2011 Apr;42(4):1116-21. doi: 10.1161/STROKEAHA.110.604652. Epub 2011 Feb 17.

11.

Dilemma of indication for thrombolysis in a patient with acute ischemic stroke treated with a novel oral anticoagulant.

Folyovich A, Varga V, Béres-Molnár KA, Vadasdi K, Bereczki D.

J Stroke Cerebrovasc Dis. 2014 Mar;23(3):580-2. doi: 10.1016/j.jstrokecerebrovasdis.2013.04.029. Epub 2013 May 28.

PMID:
23721623
12.

Dabigatran and thrombolysis: A therapeutic dilemma.

Govindarajan R, Salgado E.

Ann Neurol. 2012 Oct;72(4):625; author reply 625-6. doi: 10.1002/ana.23686. No abstract available.

PMID:
23109156
13.

Translational insights into traumatic brain injury occurring during dabigatran or warfarin anticoagulation.

Schaefer JH, Leung W, Wu L, Van Cott EM, Lok J, Whalen M, van Leyen K, Lauer A, van Ryn J, Lo EH, Foerch C.

J Cereb Blood Flow Metab. 2014 May;34(5):870-5. doi: 10.1038/jcbfm.2014.31. Epub 2014 Feb 19.

14.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
15.

Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.

Casado Naranjo I, Portilla-Cuenca JC, Jiménez Caballero PE, Calle Escobar ML, Romero Sevilla RM.

Cerebrovasc Dis. 2011;32(6):614-5. doi: 10.1159/000334578. Epub 2011 Dec 1. No abstract available.

16.

Home-monitoring of oral anticoagulation vs. dabigatran. An indirect comparison.

Alonso-Coello P, Zhou Q, Guyatt G.

Thromb Haemost. 2012 Oct;108(4):647-53. Epub 2012 Aug 23. Review.

PMID:
22918481
17.

Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.

Hohnloser SH, Oldgren J, Yang S, Wallentin L, Ezekowitz M, Reilly P, Eikelboom J, Brueckmann M, Yusuf S, Connolly SJ.

Circulation. 2012 Feb 7;125(5):669-76. doi: 10.1161/CIRCULATIONAHA.111.055970. Epub 2012 Jan 3.

18.

Subtherapeutic warfarin is not associated with increased hemorrhage rates in ischemic strokes treated with tissue plasminogen activator.

Vergouwen MD, Casaubon LK, Swartz RH, Fang J, Stamplecoski M, Kapral MK, Silver FL; Investigators of the Registry of the Canadian Stroke Network.

Stroke. 2011 Apr;42(4):1041-5. doi: 10.1161/STROKEAHA.110.599183. Epub 2011 Feb 24.

19.

Experimental modeling of recombinant tissue plasminogen activator effects after ischemic stroke.

El Amki M, Lerouet D, Coqueran B, Curis E, Orset C, Vivien D, Plotkine M, Marchand-Leroux C, Margaill I.

Exp Neurol. 2012 Dec;238(2):138-44. doi: 10.1016/j.expneurol.2012.08.005. Epub 2012 Aug 19.

PMID:
22921458
20.

Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.

Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.

J Stroke Cerebrovasc Dis. 2012 Apr;21(3):165-73. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.011. Review.

PMID:
22440950

Supplemental Content

Support Center